Healthcare Resource Utilization and Costs in Individuals Who Discontinue Liraglutide and Who Switch from Liraglutide to Once-Weekly Injectable Semaglutide
This analysis demonstrates that the cohort of people switching from liraglutide to semaglutide was associated with significantly lower HCRU and costs when compared with people discontinuing liraglutide only. These findings imply that switching to semaglutide could be a good option for people with T2D for whom liraglutide is no longer optimal.
Authors
- Yurek Paprocki (ORCID: https://orcid.org/0000-0002-5435-5179)
- Xi Tan (ORCID: https://orcid.org/0000-0002-2409-5927)
- Brenna L. Brady (ORCID: https://orcid.org/0000-0003-3210-806X)
- Lin Xie (ORCID: https://orcid.org/0000-0002-4990-9341)
Institutions
- Novo Nordisk (United States) (US)
- Diagnostics for the Real World (United Kingdom) (GB)
Publication Details
- Journal
- Diabetes Therapy
- Published
- 2025-05-16
- DOI
- https://doi.org/10.1007/s13300-025-01741-8
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 0.00